30-Second Executive Brief
Executive Assessment
AbbVie functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A biopharmaceutical company that spun off from Abbott Laboratories in 2013, now navigating the post-Humira era as biosimilar competition erodes its former flagship drug. Skyrizi and Rinvoq combined generated approximately $8.03 billion in Q2 2026 revenue (up over 24% year-over-year each), representing roughly 47% of total company revenue, while Humira revenue fell 35.9% globally (47% in the US) as AbbVie's immunology franchise successfully transitions to its next-generation drugs.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by Sarepta Therapeutics
“Dr. Severino brings more than 25 years of biopharmaceutical leadership experience, including senior executive roles at AbbVie, Amgen and Merck”
SEC 8-K exhibit (0001193125-26-335056) · Aug 5, 2026
Federal contract disclosures
Department of Veterans Affairs — $113,265: PHARM - VYALEV
USAspending.gov · Oct 1, 2025
Department of Veterans Affairs — $62,185: VYALEV - ANTIPARKINSON AGENTS
USAspending.gov · Apr 16, 2025
Department of Health and Human Services — $51,844: ABBVIE US LLC, ALLERGAN BREAST IMPLANT SUPPLIES, PIMC, YEAR 3
USAspending.gov · Nov 14, 2025
Department of Health and Human Services — $46,184: ABBVIE US LLC, ALLERGAN BREAST IMPLANT SUPPLIES, PIMC, BPA CALL, YEAR 1, 24F28001
USAspending.gov · Dec 20, 2023
Department of Veterans Affairs — $41,534: PHARM - VYALEV
USAspending.gov · Oct 1, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Pulse 2.0 — AbbVie: Skyrizi and Rinvoq generate $8.03 billion as Humira revenue falls 36%news
Latest Activity
- FilingAbbVie filed an 8-K (items 7.01,9.01)8-K
- FilingAbbVie filed an 8-K (items 8.01,9.01)8-K
- FilingAbbVie filed an 8-K (items 8.01,9.01)8-K
- FilingAbbVie filed an 8-K (items 2.02,9.01)8-K
- FilingAbbVie insider selling — $8,177,500 saleForm 4
Insider Filing Activity
Direction/size reflects a sample of the most recent filings, not every Form 4 in the window · sourced from SEC EDGAR · as of Sep 7, 2026
Insider Timing
An insider acquired 62 shares on Jun 30, 2026 — 1 day before a recorded milestone: “Skyrizi and Rinvoq reach $8.03B combined Q2 revenue”
Timing correlation only — not evidence of a causal link
An insider acquired 134 shares on Jun 30, 2026 — 1 day before a recorded milestone: “Skyrizi and Rinvoq reach $8.03B combined Q2 revenue”
Timing correlation only — not evidence of a causal link
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding AbbVie — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
AbbVie's Humira-to-Skyrizi/Rinvoq transition looks largely complete, not still unfolding
35% confidenceSkyrizi and Rinvoq now represent about 91% of AbbVie's immunology portfolio and roughly 47% of total company revenue, while Humira has fallen to just $756 million quarterly (down 35.9%) from its former position as AbbVie's flagship drug.
This is InsightNodes' own interpretive read: at $756 million and shrinking, Humira is no longer large enough to materially swing AbbVie's results either way, which means the 'post-Humira transition' narrative that has framed AbbVie's story for several years is effectively over -- the company's forward risk profile is now a two-drug concentration story (Skyrizi/Rinvoq), a meaningfully different risk than biosimilar erosion, and should be evaluated on new-indication approval risk rather than legacy-drug decline.
InsightNodes analysis of AbbVie Q2 2026 results · Aug 14, 2026
AbbVie's Timeline
A sourced, dated history of AbbVie's key moments — founding to present.
Nov 2025 · Ends Calico drug-discovery collaboration
AbbVie discontinued its 11-year drug-discovery partnership with Alphabet-backed longevity company Calico.
Jul 2026 · Skyrizi and Rinvoq reach $8.03B combined Q2 revenue
AbbVie's Q2 2026 results showed Skyrizi at $5.51 billion (+24.4%) and Rinvoq at $2.53 billion (+24.5%), together representing about 91% of the immunology portfolio, while Humira revenue fell 35.9% to $756 million.